Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing

por van Rosmalen, J, de Kok, IMCM, van Ballegooijen, M
Publicado 2012

Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study

por Jansen, EEL, Naber, SK, Aitken, CA, de Koning, HJ, van Ballegooijen, M, de Kok, IMCM
Publicado 2020

Effects of cancer screening restart strategies after COVID-19 disruption

por Kregting, L., Kaljouw, S., de Jonge, L., Jansen, E.E.L., Peterse, E.F.P., Heijnsdijk, E.A.M., van Ravesteyn, N.T., Lansdorp-Vogelaar, I., de Kok, I.M.C.M.
Publicado 2020

Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study

por Bozhar, H., McKee, M., Spadea, T., Veerus, P., Heinävaara, S., Anttila, A., Senore, C., Zielonke, N., de Kok, I.M.C.M., van Ravesteyn, N.T., Lansdorp-Vogelaar, I., de Koning, H.J., Heijnsdijk, E.A.M.
Publicado 2022